Idiosyncratic drug hepatotoxicity
The DOI matches its Crossref record; 154 of the 155 references it cites were found in a registry or an index.
Abstract
The occurrence of idiosyncratic drug hepatotoxicity is a major problem in all phases of clinical drug development and the most frequent cause of post-marketing warnings and withdrawals. This review examines the clinical signatures of this problem, signals predictive of its occurrence (particularly of more frequent, reversible, low-grade injury) and the role of monitoring in prevention by examining several recent examples (for example, troglitazone). In addition, the failure of preclinical toxicology to predict idiosyncratic reactions, and what can be done to improve this problem, is discussed. Finally, our current understanding of the pathophysiology of experimental drug hepatotoxicity is examined, focusing on acetaminophen, particularly with respect to the role of the innate immune system and control of cell-death pathways, which might provide targets for exploration and identification of risk factors and mechanisms in humans.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The current drug development process suffers from a high failure rate during clinical trials, which is partly due to inadequacy of animal models to accurately predict the toxic side-effects of drugs in humans [1,2].”
From A liver-on-a-chip platform with bioprinted hepatic spheroids (2016) · cites this paper as [2]
In the citing paper
“Drug-induced liver injury (DILI) is a common adverse drug reaction (ADR), and it can lead to liver failure and even death.[1][2][3]”
From Incidence and Etiology of Drug-Induced Liver Injury in Mainland China (2019) · cites this paper as [1]
Citations
Cites
A method for estimating the probability of adverse drug reactions
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., & Greenblatt, D. J. (1981) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1981.154 · Cited by 11,914
Tolerance, Danger, and the Extended Family
Matzinger, P. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.005015 · Cited by 4,820
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00007 · Cited by 2,227
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050
Danan, G., & Benichou, C. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90101-6 · Cited by 1,481
ACETAMINOPHEN-INDUCED HEPATIC NECROSIS. II. ROLE OF COVALENT BINDING IN VIVO
Jollow, D. J., Mitchell, J. R., Potter, W. Z., Davis, D. C., Gillette, J. R., & Brodie, B. B. (1973) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29664-1 · Cited by 1,204
Acetaminophen-induced Hepatic Necrosis
Jollow, D. J., Thorgeirsson, S. S., Potter, W. Z., Hashimoto, M., & Mitchell, J. R. (1974) · Pharmacology · doi:10.1159/000136547 · Cited by 1,092
ANDRADE, R., LUCENA, M., FERNANDEZ, M., PELAEZ, G., PACHKORIA, K., GARCIARUIZ, E., GARCIAMUNOZ, B., GONZALEZGRANDE, R., PIZARRO, A., & DURAN, J. (2005) · Gastroenterology · doi:10.1016/j.gastro.2005.05.006 · Cited by 856
Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer's Disease
Watkins, P. B. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510370044030 · Cited by 829
Research works printed but not linked: 3
- Nelson, S. D. & Bruschi, S. A. in Drug-Induced Liver Disease (eds Kaplowitz, N. & DeLeve, L.) 287–325 (Marcel Dekker, New York, 2003).
- Chien, J. Y., Thummel, K. E. & Slattery, J. T. Pharmakinetic consequence of induction of CYP2E1 by ligand stabilization. Drug Metab. Dispos. 25, 1165–1175 (1997).
- Liu, Z. -X. & Kaplowitz, N. in Clinics in Liver Disease 6, 467–486 (Elsevier, 2002).
Cited by
Items 501–600 of 999
Hepatotoxicity of Antimycotics Used for Invasive Fungal Infections: In Vitro Results
Doß, S., Potschka, H., Doß, F., Mitzner, S. R., & Sauer, M. (2017) · BioMed Research International · doi:10.1155/2017/9658018 · Cited by 25
Giri, S., & Bader, A. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.02.012 · Cited by 22
Discovery of Bakuchiol as Aim2 Inflammasome Activator and Cause Hepatotoxicity
Liu, T., Xu, G., Li, Y., Shi, W., Ren, L., Fang, Z., Liang, L., Wang, Y., Gao, Y., Xiaoyan, Z., et al. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115593 · Cited by 23
Jinno, N., Tagashira, M., Tsurui, K., & Yamada, S. (2014) · Xenobiotica · doi:10.3109/00498254.2014.894219 · Cited by 21
Pharmacogenetics of Parkinson's Disease in Clinical Practice
Corvol, J., & Poewe, W. H. (2016) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12444 · Cited by 24
Satoh, D., Iwado, S., Abe, S., Kazuki, K., Wakuri, S., Oshimura, M., & Kazuki, Y. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187072 · Cited by 21
Danjuma, M. I.-M., Sajid, J., Fatima, H., & Elzouki, A.-N. Y. (2019) · Medicine · doi:10.1097/md.0000000000018322 · Cited by 21
Greaves, P. (2007) · Elsevier eBooks · doi:10.1016/b978-044452771-4/50010-9 · Cited by 21
A microfluidic thyroid-liver platform to assess chemical safety in humans
Kuehnlenz, J., Karwelat, D., Steger‐Hartmann, T., Raschke, M., Bauer, S., Vural, Ö., Marx, U., Tinwell, H., & Bars, R. (2022) · ALTEX · doi:10.14573/altex.2108261 · Cited by 29
Udo, R., der Zee, A. H. M., Egberts, T. C. G., den Breeijen, J. H., Leufkens, H. G. M., van Solinge, W. W., & Bruin, M. L. D. (2015) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3824 · Cited by 23
Complex Gene−Chemical Interactions: Hepatic Uroporphyria As a Paradigm
Smith, A. G., & Elder, G. H. (2010) · Chemical Research in Toxicology · doi:10.1021/tx900298k · Cited by 20
Druschky, K., Toto, S., Bleich, S., Baumgärtner, J., Engel, R. R., Grohmann, R., Maier, H. B., Neyazi, A., Rudolph, Y. J., Rüther, E., et al. (2020) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2020.1819565 · Cited by 23
Bonzo, J. A., Rose, K., Freeman, K., Deibert, E., Amaral, K. B., Ferguson, S., Andersen, M. E., Witek, R. P., & LeCluyse, E. L. (2015) · Applied In Vitro Toxicology · doi:10.1089/aivt.2014.0004 · Cited by 23
Evaluation of CYP3A4 inhibition and hepatotoxicity using DMSO-treated human hepatoma HuH-7 cells
Liu, Y., Flynn, T. J., Xia, M., Wiesenfeld, P. L., & Ferguson, M. S. (2015) · Cell Biology and Toxicology · doi:10.1007/s10565-015-9306-9 · Cited by 20
Kishida, T., Onozato, T., Kanazawa, T., Tanaka, S., & Kuroda, J. (2012) · The Journal of Toxicological Sciences · doi:10.2131/jts.37.1143 · Cited by 20
Kar, P., Das, A. K., Begum, T., & Dutta, A. (2010) · Euroasian Journal of Hepato-Gastroenterology · doi:10.5005/jp-journals-10018-1181 · Cited by 25
Developing organ-on-a-chip concepts using bio-mechatronic design methodology
Christoffersson, J., van Noort, D., & Mandenius, C. (2017) · Biofabrication · doi:10.1088/1758-5090/aa71ca · Cited by 20
Pre-treatment With PLGA/Silibinin Nanoparticles Mitigates Dacarbazine-Induced Hepatotoxicity
Durymanov, M. O., Permyakova, A., & Reineke, J. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00495 · Cited by 23
Pharmacogenomic Biomarkers for Personalized Medicine
Chen, J. J., Lin, W., & Chen, H.-C. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.75 · Cited by 21
MicroRNAs in Drug-induced Liver Injury
(2014) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2014.00015 · Cited by 18
Innovation for hepatotoxicity in vitro research models: A review
Han, W., Wu, Q., Zhang, X., & Duan, Z. (2018) · Journal of Applied Toxicology · doi:10.1002/jat.3711 · Cited by 23
Buck, W. R., Waring, J. F., & Blomme, E. A. G. (2008) · Methods in molecular biology · doi:10.1007/978-1-60327-048-9_2 · Cited by 22
Agreement Among Different Scales for Causality Assessment in Drug-Induced Liver Injury
Das, S., Behera, S. K., Xavier, A. S., Velupula, S., Dkhar, S. A., & Selvarajan, S. (2018) · Clinical Drug Investigation · doi:10.1007/s40261-017-0601-5 · Cited by 19
New Approaches to Investigate Drug-Induced Hypersensitivity
Ogese, M. O., Ahmed, S. S., Alferivic, A., Betts, C. J., Dickinson, A. M., Faulkner, L., French, N. S., Gibson, A., Hirschfield, G. M., Kammuller, M. E., et al. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00333 · Cited by 22
Sphabmixay, P., Raredon, M. S. B., Wang, A. J.-S., Lee, H., Hammond, P. T., Fang, N. X., & Griffith, L. G. (2021) · Biofabrication · doi:10.1088/1758-5090/ac23aa · Cited by 20
Shin, H. K., Huang, R., & Chen, M. (2023) · Food and Chemical Toxicology · doi:10.1016/j.fct.2023.113948 · Cited by 23
Lipopolysaccharide exposure augments isoniazide‐induced liver injury
Su, Y., Zhang, Y. L., Mi, C., Jiang, Z., Sun, L., Wang, T., & Zhang, L. (2014) · Journal of Applied Toxicology · doi:10.1002/jat.2979 · Cited by 19
Chen, M., Shi, L. M., Kelly, R. J., Perkins, R., Fang, H., & Tong, W. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-s10-s3 · Cited by 19
Sun, J., Slavov, S. H., Schnackenberg, L. K., Ando, Y., Greenhaw, J. J., Yang, X., Salminen, W. F., Mendrick, D. L., & Beger, R. D. (2014) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2014.08.001 · Cited by 20
Soltanpour, Y., Hilgendorf, C., Ahlström, M. M., Foster, A. J., Kenna, J. G., Petersen, A., & Ungell, A.-L. B. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.045815 · Cited by 20
貴文, 富., Okamura, H., Yokoi, T., & Konno, Y. (2016) · Journal of Applied Toxicology · doi:10.1002/jat.3371 · Cited by 19
Microengineered systems with iPSC-derived cardiac and hepatic cells to evaluate drug adverse effects
Dame, K., & Ribeiro, A. J. S. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370220959598 · Cited by 24
Polymeric Bioinks for 3D Hepatic Printing
Sarkar, J., Kamble, S. C., & Kashikar, N. C. (2021) · Chemistry · doi:10.3390/chemistry3010014 · Cited by 19
Identification of Acetaminophen Adducts of Rat Liver Microsomal Proteins using 2D-LC-MS/MS
Golizeh, M., LeBlanc, A. R., & Sleno, L. (2015) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00317 · Cited by 21
Kawase, A., Hashimoto, R., Shibata, M., Shimada, H., & Iwaki, M. (2017) · International Journal of Toxicology · doi:10.1177/1091581817700584 · Cited by 19
Investigations toward enhanced understanding of hepatic idiosyncratic drug reactions
Liguori, M. J., & Waring, J. F. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.6.835 · Cited by 19
Long-acting GnRH analogue triptorelin therapy in central isosexual precocious puberty.
Bajpai, A., Sharma, J. N., Kabra, M., Gupta, A. K., & Menon, P. S. N. (2002) · PubMed · Cited by 19
Drug induced liver injury: from pathogenesis to liver transplantation
Germani, G., Battistella, S., Ulinici, D., Zanetto, A., Shalaby, S., Pellone, M., Gambato, M., Senzolo, M., Russo, F. P., & Burra, P. (2021) · Minerva Gastroenterology · doi:10.23736/s2724-5985.20.02795-6 · Cited by 20
Vuletić, V., Rački, V., Papić, E., & Peterlin, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137213 · Cited by 23
Systems Pharmacology: An opinion on how to turn the impossible into grand challenges
Westerhoff, H. V., Nakayama, S., Mondeel, T. D. G. A., & Barberis, M. (2015) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2015.06.006 · Cited by 21
Buchard, A., Eefsen, M., Semb, S., Andersen, S. E., Morling, N., Bendtsen, F., Larsen, F. S., & Dalhoff, K. (2011) · Clinical Toxicology · doi:10.3109/15563650.2011.639713 · Cited by 19
Ibuprofen-Induced Liver Injury in an Adolescent Athlete
Bennett, W. E., Turmelle, Y. P., & Shepherd, R. W. (2008) · Clinical Pediatrics · doi:10.1177/0009922808320797 · Cited by 18
Peng, Y., Wu, Z., Yang, H., Cai, Y., Liu, G., Li, W., & Tang, Y. (2019) · Toxicology Letters · doi:10.1016/j.toxlet.2019.05.005 · Cited by 21
Baier, V., Cordes, H., Thiel, C., Castell, J. V., Neumann, U. P., Blank, L. M., & Kuepfer, L. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.01192 · Cited by 20
Drug-Induced Liver Injury in the Setting of Chronic Liver Disease
Hoppmann, N. A., Gray, M. E., & McGuire, B. M. (2019) · Clinics in Liver Disease · doi:10.1016/j.cld.2019.09.006 · Cited by 17
Thasler, W. E., Schlott, T., Kalkuhl, A., Plän, T., Irrgang, B., Jauch, K., & Weiß, T. S. (2006) · Alternatives to Laboratory Animals · doi:10.1177/026119290603400411 · Cited by 19
Role of innate and adaptive immunity during drug-induced liver injury
Williams, C. D., & Jaeschke, H. (2012) · Toxicology Research · doi:10.1039/c2tx20032e · Cited by 19
Role of Mitochondria in Drug-Induced Cholestatic Injury
Kass, G. E. N., & Price, S. C. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.11.005 · Cited by 22
Sobol, E., Yagen, B., STEVEWHITE, H., Wilcox, K. S., LAMB, J., Pappo, O., Wlodarczyk, B. J., Finnell, R. H., & Bialer, M. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.06.006 · Cited by 18
Sleno, L., Varesio, E., & Gérard Hopfgartner, D. (2007) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.3329 · Cited by 21
Advancing hepatotoxicity assessment: current advances and future directions
Kim, Y., Kim, Y., & Kim, Y. (2025) · Toxicological Research · doi:10.1007/s43188-025-00289-w · Cited by 22
Shinde, V., Stöber, R. M., Nemade, H., Sotiriadou, I., Hescheler, J., Hengstler, J. G., & Sachinidis, A. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-2074-7_16 · Cited by 17
Sequential drug delivery for liver diseases
Huang, X., Lee, F., Teng, Y., Lingam, C. B., Chen, Z., Sun, M., Song, Z., Balachander, G. M., Leo, H. L., Guo, Q., et al. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.11.001 · Cited by 19
De-Risking Drug Discovery with ADDME — A voiding D rug D evelopment M istakes E arly
Tsaioun, K., & Jacewicz, M. S. (2009) · Alternatives to Laboratory Animals · doi:10.1177/026119290903701s10 · Cited by 19
The adaptive response (drug tolerance) helps to prevent drug-induced liver injury.
Lewis, J. H. (2012) · Europe PMC (PubMed Central) · Cited by 17
Molecular mechanism of 17α-ethinylestradiol cytotoxicity in isolated rat hepatocytes
Wan, L., & O'Brien, P. J. (2013) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2013-0267 · Cited by 17
Is There a Space-Based Technology Solution to Problems with Preclinical Drug Toxicity Testing?
Hammond, T. G., Allen, P., & Birdsall, H. H. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1942-0 · Cited by 17
Neutrophil–cytokine interactions in a rat model of sulindac-induced idiosyncratic liver injury
Zou, W., Roth, R. A., Younis, H. S., Malle, E., & Ganey, P. E. (2011) · Toxicology · doi:10.1016/j.tox.2011.10.005 · Cited by 17
In Silico Models for Hepatotoxicity
Hewitt, M., & Przybylak, K. R. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3609-0_11 · Cited by 18
Emam, M., Raey, M. A. E., El-Haddad, A. E., Awdan, S. A. E., Rabie, A., El-Ansari, M. A., Sobeh, M., Osman, S. M., & Wink, M. (2018) · Molecules · doi:10.3390/molecules24010138 · Cited by 18
Harada, H., Endo, T., Momose, Y., & Kusama, H. (2009) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.3912 · Cited by 17
Khetani, S. R. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.12.005 · Cited by 17
Scalfaro, E., Streefkerk, H. J., Merz, M., Meier, C., & Lewis, D. (2017) · Drug Safety · doi:10.1007/s40264-017-0541-2 · Cited by 16
Generation of Scalable Hepatic Micro-Tissues as a Platform for Toxicological Studies
Darakhshan, S., Pour, A. B., Kowsari‐Esfahan, R., Vosough, M., Montazeri, L., Ghanian, M. H., Baharvand, H., & Piryaei, A. (2020) · Tissue Engineering and Regenerative Medicine · doi:10.1007/s13770-020-00272-6 · Cited by 17
Wang, K., Rao, J., Zhang, T., Gao, Q., Zhang, J., Guang, C., Ding, L., & Qiu, F. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s274627 · Cited by 16
Advances and Challenges in Modeling Cannabidiol Pharmacokinetics and Hepatotoxicity
Beers, J. L., Zhou, Z., & Jackson, K. D. (2024) · Drug Metabolism and Disposition · doi:10.1124/dmd.123.001435 · Cited by 18
Herbal hepatotoxicity: a case of difficult interpretation.
Valente, G. C. B., Sanges, M., Campione, S., Bellevicine, C., Franchis, G. D., Sollazzo, R., Mattera, D., Cimino, L., Vecchione, R., & D'Arienzo, A. (2010) · PubMed · Cited by 17
Case‐crossover study of hospitalization for acute hepatitis in Chinese herb users
Lee, C., Wang, J., & Chen, P. (2008) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2008.05511.x · Cited by 16
Jiang, J., Mathijs, K., Timmermans, L., Claessen, S. M. H., Hecka, A., Weusten, J. J. A. M., Peters, R. A. H., van Delft, J. H. M., Kleinjans, J. C. S., Jennen, D. G. J., et al. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.07.014 · Cited by 18
Ma, L., Pan, Y., Sun, M. Y., Shen, H., Zhao, L., & Guo, Y. (2018) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000574 · Cited by 16
Hepatotoxicity of Immunosuppressive Drugs
Reuben, A. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-387817-5.00031-5 · Cited by 17
Species-specific toxicity of troglitazone on rats and human by gel entrapped hepatocytes
Shen, C., Meng, Q., & Zhang, G. (2011) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2011.10.020 · Cited by 16
The role of cytochrome P4502E1 in ethanol mediated diseases: a narrative update
Zakhari, S., Neuman, M. G., & Seitz, H. K. (2025) · Alcohol and Alcoholism · doi:10.1093/alcalc/agaf014 · Cited by 17
Lee, T., & Posma, J. M. (2025) · Journal of Cheminformatics · doi:10.1186/s13321-025-01068-3 · Cited by 20
Wang, Y., Lai, R., Zong, P., Xu, Q., Shang, J., Zhang, X., Zhong, W., Tang, J. T., Han, X., Chen, C., et al. (2021) · Journal of International Medical Research · doi:10.1177/03000605211005945 · Cited by 16
Rodríguez, A., García-García, I., de Soto, L. M., Huertas, A. G. L. D. L., Borobia, A. M., González‐Torbay, A., Akatbach-Bousaid, I., González‐Muñoz, M., & Ramı́rez, E. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.819589 · Cited by 15
Şahin, S., Çakmak, A., Göçmen, A. Y., & Kaymak, E. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02937-0 · Cited by 16
Characteristic molecular and proteomic signatures of drug‐induced liver injury in a rat model
Eun, J. W., Bae, H. J., Shen, Q., Park, S. J., Kim, H.-S., Shin, W. C., Yang, H. D., Jin, C., You, J. S., Kang, H. J., et al. (2014) · Journal of Applied Toxicology · doi:10.1002/jat.3062 · Cited by 15
Chiang, T.-S., Yang, K., Zheng, S.-K., Chiou, L., Hsu, W., Lin, F., Huang, G., & Lee, M. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.04.014 · Cited by 15
A pre-marketing ALT signal predicts post-marketing liver safety
Moylan, C. A., Suzuki, A., Papay, J. I., Yuen, N., Ames, M. H., & Hunt, C. M. (2012) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2012.05.016 · Cited by 15
Hepatotoxicity assay using human hepatocytes trapped in microholes of a microfluidic device
Yeon, J. H., Na, D., & Park, J. (2010) · Electrophoresis · doi:10.1002/elps.201000122 · Cited by 17
Assessing the compatibility of primary human hepatocyte culture within porous silk sponges
Kukla, D. A., Stoppel, W. L., Kaplan, D. L., & Khetani, S. R. (2020) · RSC Advances · doi:10.1039/d0ra04954a · Cited by 15
Perspectives of future lung toxicology studies using human pluripotent stem cells
Masui, A., Hirai, T., & Gotoh, S. (2022) · Archives of Toxicology · doi:10.1007/s00204-021-03188-9 · Cited by 18
Self-Masked Aldehyde Inhibitors of Human Cathepsin L Are Potent Anti-CoV-2 Agents
Zhu, J., Li, L., Drelich, A. K., Chenna, B., Mellott, D. M., Taylor, Z. W., Tat, V., Garcia, C. Z., Katzfuss, A., Tseng, C.-T. K., et al. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.867928 · Cited by 15
Yun, J.-W., Kim, C.-W., Bae, I., Park, Y.-H., Chung, J., Lim, K., & Kang, K. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.05.018 · Cited by 15
Deficiency of Interleukin-15 Enhances Susceptibility to Acetaminophen-Induced Liver Injury in Mice
Hou, H.-S., Liao, C., Sytwu, H., Liao, N., Huang, T., Hsieh, T., & Chu, H.-C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044880 · Cited by 18
Mechanisms of Cell Death and Relevance to Drug Toxicity
Dara, L., Han, D., & Kaplowitz, N. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-387817-5.00006-6 · Cited by 16
Self-citationHuang, Y., Zhang, Y., Wu, K., Tan, X., Lan, T., & Wang, G. (2024) · Molecules · doi:10.3390/molecules29112663 · Cited by 16
Ocete‐Hita, E., Salmerón‐Fernández, M., Urrutia‐Maldonado, E., Muñoz‐de‐Rueda, P., Salmerón-Ruiz, M. A., Martinez‐Padilla, M., & Ruiz‐Extremera, A. (2016) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000001502 · Cited by 16
Battista, C., Yang, K., Stahl, S. H., Mettetal, J. T., Watkins, P. B., Siler, S. Q., & Howell, B. A. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfy191 · Cited by 14
Ginseng-Related Drug-Induced Liver Injury
Lin, K., Lin, A., Linn, S., Hlaing, P. P., Vasudevan, V. P., & Reddy, M. (2018) · Case Reports in Gastroenterology · doi:10.1159/000490525 · Cited by 16
Hepatotoxicants induce cytokine imbalance in response to innate immune system
Goto, S., Deguchi, J., Nishio, N., Nomura, N., & Funabashi, H. (2015) · The Journal of Toxicological Sciences · doi:10.2131/jts.40.389 · Cited by 16
Spred-2 deficiency exacerbates acetaminophen‐induced hepatotoxicity in mice
Wakabayashi, H., Ito, T., Fushimi, S., Nakashima, Y., Itakura, J., Liu, Q., Win, M. M., Cuiming, S., Chen, C., Sato, M., et al. (2012) · Clinical Immunology · doi:10.1016/j.clim.2012.07.002 · Cited by 15
Hepatitis aguda grave asociada al consumo de té de Aloe vera
Curciarello, J. O., Ortúzar, S. D., Borzi, S. M., & Bosia, D. (2008) · Gastroenterología y Hepatología · doi:10.1157/13125590 · Cited by 14
Disposable sensors for rapid screening of mutated genes
García‐Mendiola, T., Fernández‐Barrena, M. G., Revenga‐Parra, M., Núñez, A., Casero, E., Pariente, F., Prìeto, J., & Lorenzo, E. (2010) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-010-4029-5 · Cited by 14
Biomarkers of Drug Toxicity and Safety Evaluation
Anadón, A., Martínez-Larrañaga, M. R., Arés, I., & Martínez, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814655-2.00038-4 · Cited by 18
Predictive Toxicogenomics in Preclinical Discovery
Barros, S. A., & Martin, R. B. (2008) · Methods in molecular biology · doi:10.1007/978-1-60327-048-9_5 · Cited by 14
How can We Discover Safer Drugs?
Hornberg, J. J., & Mow, T. J. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.15 · Cited by 14
Sun, Y., Yin, S., Cui, J., Wang, Z., Han, Y., Ma, D., Wang, S., Wu, J., Cao, Y., Jiang, C., et al. (2024) · Nano Research · doi:10.1007/s12274-023-5940-3 · Cited by 13
Identification of Protein Targets of Reactive Metabolites of Tienilic Acid in Human Hepatocytes
Koen, Y. M., Sarma, D., Williams, T. D., Galeva, N. A., Obach, R. S., & Hanzlik, R. P. (2012) · Chemical Research in Toxicology · doi:10.1021/tx300103j · Cited by 13
Metadata
- Authors
- Kaplowitz, N.
- Affiliations
- University of Southern California (US)
- Corresponding author
- Kaplowitz, Neil
- ORCID
- Kaplowitz, Neil
- Venue
- Nature Reviews Drug Discovery
- Published
- 2005-06
- Volume
- 4
- Issue
- 6
- Pages
- 489-499
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2017783406
- Cited by
- 1,054
- References
- 155
- Citations by year
- 2026: 29 · 2025: 35 · 2024: 35 · 2023: 44 · 2022: 31 · 2021: 49 · 2020: 45 · 2019: 48 · 2018: 54 · 2017: 66 · 2016: 72 · 2015: 55 · 2014: 64 · 2013: 57 · 2012: 52
- FWCI
- 5.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Keywords
- drug-induced liver injury, troglitazone, preclinical toxicology, hepatotoxicity prediction, pharmacovigilance, acetaminophen hepatotoxicity, innate immune system, cell death pathways, drug withdrawal, post-marketing surveillance
- MeSH terms
- Animals, Pharmaceutical Preparations, Humans, Liver, Liver Diseases, Chemical and Drug Induced Liver Injury, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.